Large white/landrace piglets (mass 11 to 21 kg) were exposed to aerosolized alkaline glycine diluent (n=2) or inhaled aerosolized prostacyclin (n=2) for five to eight hours. Pigs receiving these aerosols developed mild acute sterile tracheitis, involving the superficial layers of the trachea, shown histologically and ultrastructurally. Pigs receiving the diluent aerosol also showed mild inflammatory changes in the bronchioles. These findings suggest caution with the use of high volumes of aerosolized alkaline glycine diluent during inhaled aerosolized prostacyclin therapy.
SilvesterW.Prostacyclin in review: its physiology and role in intensive care.Intensive Care World1997; 15: 22–39.
2.
BurghuberO.C., SilberbauerK., HaberP., SinzingerH., ElliottM., LeithnerC.Pulmonary and antiaggregatory effects of prosta-cyclin after inhalation and intravenous infusion.Respiration1984; 45: 450–454.
3.
UbatubaF.B., MoncadaS., VaneJ.R.The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formation in vivo and bleeding time.Thromb Haemost1979; 41: 425–435.
4.
MoncadaS., VaneJ.R.Prostacyclin and blood coagulation.Drugs1981; 21: 430–437.
5.
SzczeklikA., GryglewskiR.J., NizankowskaE., NizankowskaR., MusialJ.Pulmonary and anti-platelet effects of intravenous and inhaled prostacyclin in man.Prostaglandins1978; 16: 651–660.
6.
WelteM., ZwisslerB., HabazettlH., MessmerK.PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction.Eur Surg Res1993; 25: 329–340.
7.
BindlL., FahnenstichH., PeukertU.Aerosolized prostacyclin for pulmonary hypertension in neonates.Arch Dis Child1994; 71: F214–F216.
8.
HaasN.A., Schulze-NeickI., LangeP.E.Intratracheal prosta-cyclin for resuscitation in primary pulmonary hypertension.Lancet1995; 346: 643.
9.
van HeerdenP.V., WebbS.A.R., HeeG., CorkeronM., ThompsonW.R.Inhaled aerosolized prostacyclin as a selective pulmonary vasodilator for the treatment of severe hypoxaemia.Anaesth Intensive Care1996; 24: 87–90.
10.
WebbS.A.R., StottS., van HeerdenP.V.The use of inhaled aerosolized prostacyclin (IAP) in the treatment of pulmonary hypertension secondary to pulmonary embolism.Intensive Care Med1996; 22: 353–355.
11.
van HeerdenP.V., BlytheD., WebbS.A.R.Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS—A pilot study.Anaesth Intensive Care1996; 24: 564–568.
ZwisslerB., WelteM., HablerO., KleenM., MessmerK.Effects of inhaled prostacyclin as compared with inhaled nitric oxide in a canine model of pulmonary microembolism and oleic acid edema.J Cardiothorac Vasc Anesth1995; 9: 634–640.
14.
SchranzD., HuthR., WippermanC., RitzerfeldS., SchmittF., OelertH.Nitric oxide and prostacyclin lower suprasystemic pulmonary hypertension after cardiopulmonary bypass.Eur J Pediatr1993; 152: 793–796.
15.
WalmrathD., SchneiderT., SchermulyR., OlschewskiH., GrimmingerF., SeegerW.Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome.Am J Respir Crit Care Med1996; 153: 991–996.
16.
ZwisslerB., KemmingG., HablerO.. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome.Am J Respir Crit Care Med1996; 154: 1671–1677.
17.
BookeM., BradfordD.W., HinderF.. Effects of inhaled nitric oxide and nebulized prostacyclin on hypoxic pulmonary vasoconstriction in anesthetized sheep.Crit Care Med1996; 24: 1841–1848.
18.
HaraldssonA., Kieler-JensenN., Nathorst-WestfeltU., BerghC.H., RickstenS.Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance.Chest1998; 114: 780–786.
19.
PappertD., BuschT., GerlachH., LewandowskiK., RadermacherP., RossaintR.Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome.Anesthesiology1995; 82: 1507–1511.
20.
EichelbronnerO., ReineltH., WiedeckH., MezodyM., RossaintR., GeorgieffM.. Aerosolized prostacyclin and inhaled nitric oxide in septic shock - different effects on splanchnic oxygenation?Intens Care Med1996; 22: 880–887.
21.
van HeerdenP.V., PowerB.M., LeonardR.C.Re: Delivery of inhaled aerosolised prostacyclin (IAP).Anaesth Intens Care1996; 24: 624–625.
22.
HablerO., KleenM., ZwisslerB.. Inhalation of prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs.Intens Care Med1996; 22: 426–433.
23.
HablerO., KleenM., TakenakaS.. Eight hours’ inhalation of prostacyclin (PGI2) in healthy lambs: effects on tracheal, bronchial, and alveolar morphology.Intensive Care Med1996; 22: 1232–1238.
24.
BiancoS., RobuschiM., GrugniA., CeseraniR., GandolfiC.Effect of prostacyclin on antigen induced immediate bron-choconstriction in asthmatic patients.Prostaglandins Med1979; 3: 39–45.
25.
DoyleP., SwartM., KongA.Inhaled prostacyclin as a selective pulmonary vasodilator.Anaesth Intensive Care1996; 24: 514–515.
26.
BeinT., PfeiferM., RieggerG.A.J., TaegerK.Continuous intra-arterial measurement of oxygenation during aerosolized prostacyclin administration in severe respiratory failure.N Engl J Med1994; 331: 335–336.
27.
BeinT., KeylC., PfeiferM., MetzC.Administration of aerosolized prostacyclin in patients with severe respiratory failure and pulmonary hypertension.Chest1995; 108: 119S.
28.
WetzelR.C.Aerosolized prostacyclin. In search of the ideal pulmonary vasodilator.Anesthesiology1995; 82: 1315–1317.
29.
WalmrathD., SchneiderT., PilchJ., SchermulyR., GrimmingerF., SeegerW.Effects of aerosolized prostacyclin in severe pneumonia. Impact of fibrosis.Am J Respir Crit Care Med1995; 151: 724–730.
30.
OlschewskiH., WalmrathD., SchermulyR., GhofraniA., GrimmingerF., SeegerW.Aerosolized prostacyclin and iloprost in severe pulmonary hypertension.Ann Intern Med1996; 124: 820–824.
31.
StrickerH., DominghettiG., WaldispuehlB.Transbronchial vasodilator therapy with aerosolized prostacyclin (PG12 ae) in patients (p) with pulmonary hypertension (PH) associated with ARDS.Intensive Care Med1996; 22: S408.
32.
Kieler-JensenN., MiloccoI., KirnoK., HoultzE., RickstenS.Effects of prostacyclin on myocardial hemodynamics and metabolism after coronary artery bypass grafting.J Cardiothorac Vasc Anesth1996; 10: 741–747.
33.
HaraldssonA., Kieler-JensenN., RickstenS.Inhaled prosta-cyclin for treatment of pulmonary hypertension after cardiac surgery or heart transplantation: A pharmacodynamic study.J Cardiothorac Vasc Anesth1996; 10: 864–868.
34.
SantakB., SchreiberM., KuenP., LangD., RadermacherP.Prostacyclin aerosol in an infant with pulmonary hypertension.Eur J Pediatr1995; 154: 233–235.
35.
BeinT., MetzC., KeylC., SendtnerE., PfeiferM.Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in severe respiratory failure using a ventilator nebulizing system.J Cardiovasc Pharmacol1996; 27: 583–586.
36.
ScheerenT., RadermacherP.Prostacyclin (PGI2): new aspects of an old substance in the treatment of critically ill patients.Intensive Care Med1997; 3: 146–158.
37.
RoystonD.Inhalation agents for pulmonary hypertension.Lancet1993; 342: 941–942.
38.
SodittV., AringC., GroneckP.Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn.Intensive Care Med1997; 23: 1275–1278.
39.
McGinnP.V., BlackA.J.R.Use of nebulised prostacyclin to ascertain reversibility of secondary pulmonary hypertension.Aust N Z J Med1996; 26: 234–235.
40.
MikhailG., GibbsS.R., RichardsonM.. An evaluation of nebulized prostacyclin in patients with primary and secondary pulmonary hypertension.Eur Heart J1997; 18: 1499–1504.
